This company has been marked as potentially delisted and may not be actively trading. NASDAQ:STML Stemline Therapeutics (STML) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Stemline Therapeutics Stock (NASDAQ:STML) 30 days 90 days 365 days Advanced Chart Get Stemline Therapeutics alerts:Sign Up Key Stats Today's Range$11.83▼$11.8350-Day Range$11.83▼$11.8352-Week Range$3.21▼$18.22Volume1,084 shsAverage Volume1.52 million shsMarket Capitalization$621.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York. Read More Receive STML Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stemline Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STML Stock News HeadlinesStemline’s Promising Study on Elacestrant for Metastatic Breast CancerAugust 4, 2025 | tipranks.comStemline’s Promising Phase 3 Study on Elacestrant for Early Breast CancerJuly 9, 2025 | tipranks.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.August 29 at 2:00 AM | Brownstone Research (Ad)Trade These 7 Stocks Under $10 for Huge ProfitsApril 10, 2022 | thestreet.comBreakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML)October 26, 2021 | finance.yahoo.comSee More Headlines STML Stock Analysis - Frequently Asked Questions How were Stemline Therapeutics' earnings last quarter? Stemline Therapeutics Inc (NASDAQ:STML) released its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.08. The biopharmaceutical company earned $13.33 million during the quarter, compared to the consensus estimate of $13.40 million. Stemline Therapeutics had a negative net margin of 150.30% and a negative trailing twelve-month return on equity of 48.14%. What other stocks do shareholders of Stemline Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stemline Therapeutics investors own include TG Therapeutics (TGTX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), Sorrento Therapeutics (SRNE) and ZIOPHARM Oncology (ZIOP). Company Calendar Last Earnings11/07/2019Today8/29/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:STML CIK1264587 Webwww.stemline.com Phone646-502-2311FaxN/AEmployees92Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$76.82 million Net Margins-150.30% Pretax MarginN/A Return on Equity-48.14% Return on Assets-41.35% Debt Debt-to-Equity RatioN/A Current Ratio7.43 Quick Ratio7.37 Sales & Book Value Annual Sales$43.22 million Price / Sales14.37 Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book3.63Miscellaneous Outstanding Shares52,511,000Free FloatN/AMarket Cap$621.21 million OptionableOptionable Beta1.78 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:STML) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stemline Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Stemline Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.